Page 44 - Read Online

Garro-Núñez et al. J Transl Genet Genom 2022;6:361-74 https://dx.doi.org/10.20517/jtgg.2022.10 Page 373

~700000 individuals of European ancestry. Hum Mol Genet 2018;27:3641-9. DOI PubMed PMC
52. Noronha NY, Barato M, Sae-lee C, et al. Novel Zinc-related differentially methylated regions in leukocytes of women with and
without obesity. Front Nutr 2022;9:785281. DOI
53. Satake W, Nakabayashi Y, Mizuta I, et al. Genome-wide association study identifies common variants at four loci as genetic risk
factors for Parkinson’s disease. Nat Genet 2009;41:1303-7. DOI PubMed
54. Yan Y, Tian J, Mo X, et al. Genetic variants in the RAB7L1 and SLC41A1 genes of the PARK16 locus in chinese parkinson’s
disease patients. Int J Neurosci 2011;121:632-6. DOI PubMed
55. Tucci A, Nalls MA, Houlden H, et al. Genetic variability at the PARK16 locus. Eur J Hum Genet 2010;18:1356-9. DOI PubMed
PMC
56. Parkinson’s Disease Genomics Consortium (IPDGC); Wellcome Trust Case Control Consortium 2 (WTCCC2). A two-stage meta-
analysis identifies several new loci for Parkinson’s disease. PLoS Genet 2011;7:e1002142. DOI
57. Rudakou U, Yu E, Krohn L, et al. Targeted sequencing of Parkinson’s disease loci genes highlights SYT11, FGF20 and other
associations. Brain 2021;144:462-72. DOI PubMed PMC
58. Gan-Or Z, Bar-Shira A, Dahary D, et al. Association of sequence alterations in the putative promoter of RAB7L1 with a reduced
parkinson disease risk. Arch Neurol 2012;69:105-10. DOI PubMed
+ 2+
59. Kolisek M, Sponder G, Mastrototaro L, et al. Substitution p.A350V in Na /Mg exchanger SLC41A1, potentially associated with
Parkinson’s disease, is a gain-of-function mutation. PLoS One 2013;8:e71096. DOI
2+
+
60. Lin CH, Wu YR, Chen WL, et al. Variant R244H in Na /Mg exchanger SLC41A1 in Taiwanese Parkinson’s disease is associated
with loss of Mg2+ efflux function. Parkinsonism Relat Disord 2014;20:600-3. DOI PubMed
61. Bai Y, Dong L, Huang X, Zheng S, Qiu P, Lan F. Associations of rs823128, rs1572931, and rs823156 polymorphisms with reduced
Parkinson’s disease risks. Neuroreport 2017;28:936-41. DOI PubMed PMC
62. Singh S, Seth PK. Functional association between NUCKS1 gene and Parkinson disease: A potential susceptibility biomarker.
Bioinformation 2019;15:548-56. DOI PubMed PMC
63. Pihlstrøm L, Rengmark A, Bjørnarå KA, et al. Fine mapping and resequencing of the PARK16 locus in Parkinson’s disease. J Hum
Genet 2015;60:357-62. DOI PubMed
64. Nalls MA, Pankratz N, Lill CM, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for
Parkinson’s disease. Nat Genet 2014;46:989-93. DOI PubMed PMC
65. Hauser DN, Hastings TG. Mitochondrial dysfunction and oxidative stress in Parkinson’s disease and monogenic parkinsonism.
Neurobiol Dis 2013;51:35-42. DOI PubMed PMC
66. Subramaniam SR, Chesselet MF. Mitochondrial dysfunction and oxidative stress in Parkinson’s disease. Prog Neurobiol 2013;106-
107:17-32. DOI PubMed PMC
67. Mann VM, Cooper JM, Daniel SE, et al. Complex I, iron, and ferritin in Parkinson’s disease substantia nigra. Ann Neurol
1994;36:876-81. DOI
68. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson’s disease. J
Neurochem 1990;54:823-7. DOI
69. González-Rodríguez P, Zampese E, Stout KA, et al. Disruption of mitochondrial complex I induces progressive parkinsonism. Nature
2021;599:650-6. DOI PubMed PMC
2+
70. Votyakova TV, Reynolds IJ. Ca -induced permeabilization promotes free radical release from rat brain mitochondria with partially
inhibited complex I. J Neurochem 2005;93:526-37. DOI PubMed
71. Koopman WJ, Verkaart S, Visch HJ, et al. Inhibition of complex I of the electron transport chain causes O -mediated mitochondrial
2
outgrowth. Am J Physiol Cell Physiol 2005;288:C1440-50. DOI PubMed
72. Jenner P. Oxidative stress in Parkinson’s disease. Ann Neurol 2003;53:S26-36. DOI PubMed
73. Hastings TG. Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J Neurochem 1995;64:919-24. DOI PubMed
74. Berman SB, Hastings TG. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain
mitochondria: implications for Parkinson’s disease. J Neurochem 1999;73:1127-37. DOI PubMed
75. Buc-Calderon P, Roberfroid M. Increase in the survival time of mice exposed to ionizing radiation by a new class of free radical
scavengers. Experientia 1990;46:708-10. DOI PubMed
76. Suzen S, Gurkok G, Coban T. Novel N-acyl dehydroalanine derivatives as antioxidants: studies on rat liver lipid peroxidation levels
and DPPH free radical scavenging activity. J Enzyme Inhib Med Chem 2006;21:179-85. DOI PubMed
77. Chang KH, Chen CM, Chen YC, et al. Association between PARK16 and Parkinson’s disease in the Han Chinese population: a meta-
analysis. Neurobiol Aging 2013;34:2442.e5-9. DOI PubMed
78. Tan EK, Kwok HH, Tan LC, et al. Analysis of GWAS-linked loci in Parkinson disease reaffirms PARK16 as a susceptibility locus.
Neurology 2010;75:508-12. DOI PubMed PMC
79. Yan YP, Mo XY, Tian J, et al. An association between the PARK16 locus and Parkinson’s disease in a cohort from eastern China.
Parkinsonism Relat Disord 2011;17:737-9. DOI PubMed
80. Simón-Sánchez J, Schulte C, Bras JM, et al. Genome-wide association study reveals genetic risk underlying Parkinson’s disease. Nat
Genet 2009;41:1308-12. DOI PubMed PMC
81. Deng X, Xiao B, Allen JC, et al. Parkinson’s disease GWAS-linked Park16 carriers show greater motor progression. J Med Genet
2019;56:765-8. DOI PubMed PMC